Skip to main content
All lobbying filings

MERCK & CO, INC.

Lobbying for MERCK & CO INC

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · New Jersey · House · Senate · $2,600,000.00 expenses · posted Apr 21, 2025

Official filing document

 Bills named in this filing 9
  • HR 1244
    Reducing Drug Prices for Seniors Act
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 1503
    Stop Forced Organ Harvesting Act of 2025
  • S 2916
    Long-Distance Corridor Relief Act
  • HR 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
  • S 1040
    Drug Competition Enhancement Act
  • S 1339
    Stop CCP Money Laundering Act of 2025
  • S 2076
    HCBS Relief Act of 2025
  • HR 8467
    ZOMBIE Act
 Lobbying activity 4
Health Issues

H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.

Medicare/Medicaid

H.R. 1244, Reducing Drug Prices for Seniors Act Issues relating to, Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; FY-2025 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP);

Taxation/Internal Revenue Code

Issues relating to, Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes.

Animals

H.R. 8467, Farm, Food, and National Security Act of 2024 Issues relating to, United Stated Department of Agriculture; Animal and Plant Health Inspection Service; Final Rule regarding use of electronic identification eartags as official identification in cattle and bison (89 Fed. Reg. 39,541-39,566, May 9, 2024)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem